A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Key Inclusion Criteria:

Before surgery:

- Body mass index (BMI) of 18.0 to 38.0 kilogram per meter square (kg/m^2)

- Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair,
without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic
block) not to include base wedge procedure

After surgery:

- Subject reported pain of greater than or equal to (>=) 4 on Numeric Pain Rating Scale
(NPRS) and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within
9 hours after removal of the popliteal sciatic block on Day 1

- Subject is lucid and able to follow commands

- All analgesic guidelines were followed during and after the bunionectomy

Key Exclusion Criteria:

Before surgery:

- History in the past 10 years of malignancy, except for squamous cell skin cancer,
basal cell skin cancer, and Stage 0 cervical carcinoma in situ

- History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)

- History of abnormal laboratory results >=2.5*upper limit of normal (ULN)

- History of peripheral neuropathy

- A known or clinically suspected infection with human immunodeficiency virus or
hepatitis B or C viruses

- Prior medical history of bunionectomy or other foot surgery on the index foot

- History of peptic ulcer disease, or intolerance or unwillingness to receive ibuprofen

After surgery:

- Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery

Other protocol defined inclusion/exclusion criteria may apply